Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
Veracyte Inc VCYT
$46.08
β² +1.88%
(+$0.85)
Open
$46.00
Prev Close
$45.23
Day Range
$45.21 β $47.52
52W Range
$29.46 β $60.91
Market Cap
$3.70B
P/E (TTM)
31.76
Beta
2.02
EPS (TTM)
$1.40
π Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2013-10-30 |
| Shares Out. | 79,790,000 |
| Website | veracyte.com/ β |
| Phone | 13026587581 |
| Employees | 755 |
| Revenue | $150.3M |
| Gross Profit | $108.5M |
| Net Income | $25.5M |
| Free Cash Flow | $166.0M |
| Total Assets | $1.49B |
| Total Liabilities | $98.0M |
| Equity | $1.39B |
About Veracyte Inc
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
Veracyte Inc is a publicly traded company under the ticker symbol VCYT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
π Analyst Ratings
19 analysts (2026-09-01)
π° Latest News for VCYT
Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal
Here's Why You Should Retain Integer Holdings Stock in Your Portfolio
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
Fresenius Medical Care Reshapes China Portfolio for Long-Term Growth
Phase III Trial Demonstrates Veracyteβs Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation
Is This the Right Time to Add Labcorp Stock to Your Portfolio?
Veracyte To Present New Findings From Retrospective Ancillary Analysis Of Randomized Phase III NRG/RTOG 0815 Trial At 2026 ASTRO Annual Meeting

